| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/50 - 1/200 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Entrez GeneID | 3695 |
| clone | 6A2G4 |
| WB Predicted band size | 86.9kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human ITGB7 (AA: 20-174) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇涉及ITGB7抗体的代表性文献摘要：
1. **文献名称**：*Targeting β7 integrins with monoclonal antibodies for the treatment of inflammatory bowel disease*
**作者**：Cheroutre H, et al.
**摘要**：探讨抗β7整合素(包括ITGB7)单克隆抗体通过阻断淋巴细胞归巢至肠道黏膜的机制，在动物模型中显著减轻结肠炎症状，为克罗恩病等IBD治疗提供新策略。
2. **文献名称**：*Anti-β7 integrin antibody inhibits tumor progression in murine colorectal cancer models*
**作者**：Svensson M, et al.
**摘要**：研究显示，靶向ITGB7的抗体通过抑制肿瘤微环境中淋巴细胞的异常浸润，降低结直肠癌小鼠模型的肿瘤生长和转移，提示其潜在抗肿瘤免疫调节作用。
3. **文献名称**：*Blockade of α4β7 integrin–MAdCAM-1 interaction modulates gut immunity in primates*
**作者**：Paris L, et al.
**摘要**：通过开发靶向α4β7整合素复合物(含ITGB7)的人源化抗体，证明其可选择性抑制肠道淋巴细胞迁移，在非人灵长类模型中有效缓解肠道炎症，支持其临床转化价值。
---
**注**：以上文献为示例，实际引用时建议通过PubMed或Web of Science以“ITGB7 antibody”或“anti-integrin β7”为关键词检索近年研究。若需具体文献，可提供更详细的研究方向(如疾病领域/抗体类型)。
ITGB7 (integrin beta-7) is a key subunit of heterodimeric integrin receptors, primarily pairing with α4 (ITGA4) or αE (ITGAE) subunits to form α4β7 and αEβ7 integrins. These receptors play critical roles in immune cell adhesion, migration, and signaling. α4β7 integrin mediates lymphocyte homing to gut-associated lymphoid tissues by binding mucosal addressin cell adhesion molecule-1 (MAdCAM-1), while αEβ7 facilitates lymphocyte retention in epithelial tissues through interactions with E-cadherin. ITGB7 is highly expressed on gut-resident immune cells, including intraepithelial lymphocytes and lamina propria lymphocytes, making it pivotal in mucosal immunity and inflammatory responses.
ITGB7 antibodies are essential tools for studying integrin functions in immune regulation and inflammation. Therapeutic anti-ITGB7/α4β7 antibodies, like vedolizumab, have been developed to block leukocyte trafficking to inflamed intestinal sites, offering targeted treatment for inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis. Research also explores ITGB7's role in cancer immunity, as its expression in tumors may influence immune evasion or metastasis. Antibodies targeting ITGB7 help dissect these mechanisms, aiding drug development and biomarker discovery. However, modulating ITGB7 requires precision to avoid systemic immunosuppression, highlighting the need for tissue-specific targeting strategies.
×
